Previous studies have reported the associations of genetic variations in VEGF, VEGFR1, VEGFR2, VEGFR3, ABCB1, NR1/2, NR1/3 and CYP3A5 genes with sunitinib treatment outcome.[16–20] Notably, genetic polymorphisms on VEGF, VEGFR, VEGFA haplotype and eNOS shown to be associated with sunitinib-induced hypertension as well as variants on ABCG2 associated with the risk of sunitinib related toxicity in mRCC patients.[16, 21, 22]. The gene discussed is VEGFA; the disease is hypertensive disorder.